Goutham Sunny

Due to an unexpectedly busy schedule, a few postponed personal commitments and projects, and several fast-approaching deadlines, I’ll be taking a break from posting tweets and updates for the next couple of months. I hope to be back by mid-September. I’ll still be around, reading…

Even though I've used SG only once and I've never used DatoDxD - as an academic exercise I wanted to review the ADR profile of both ADCs. Made a small infographic card for the same. Hope it is useful for ppl who need it. @OncBrothers @SuyogCancer @PTarantinoMD @dr_yakupergun

Radio- chemotherapy induced oral mucositis - prevention and management doi.org/10.1038/s41368…

Myelofibrosis - recommendations for Asia Pacific from APAC-MF Alliance doi.org/10.1200/OP-24-…

ASCO updates stage IV NSCLC with driver mutation guideline #lcsm ascopubs.org/doi/full/10.12…

ASCO updates stage IV NSCLC without driver mutation guidelines #LCSM doi.org/10.1200/JCO-25…

SANO Trial Summary: Active Surveillance vs Surgery in Esophageal Cancer 🥼🫁 📌 Context: Patients with locally advanced esophageal cancer achieving clinical complete response (cCR) after neoadjuvant chemoradiotherapy (nCRT) may safely opt for active surveillance instead of…

EGFR-mutant NSCLC: Evolving Landscape 🧬💊 Targeted EGFR TKIs have transformed NSCLC care, now used from early to metastatic stages. 🫁 While combinations improve PFS, they raise toxicity and cost—making biomarker-driven patient selection essential. New insights into…

🧪 Bulumtatug Fuvedotin (BFv): A Promising Nectin-4 Targeted ADC in Solid Tumors 🔍 Study Highlights: •First-in-human, multi-phase trial of bulumtatug fuvedotin (BFv), a Nectin-4–targeting ADC delivering MMAE, in patients with advanced solid tumors (N=274). •Included patients…

🫀 Cardiotoxicity in Breast Cancer Survivors: A Growing Concern in the HER2 Era 🔍 Overview: •Adjuvant radiation therapy (RT) improves locoregional control and disease-free survival in breast cancer. •However, incidental cardiac exposure from RT and HER2-targeted therapies…

🧠 Fatigue in Long-Term Cancer Survivors: A Predictor of Mortality 🔍 Study Overview: CAESAR study assessed fatigue in 6057 breast, prostate, or colorectal cancer survivors (5–16 years post-diagnosis) vs cancer-free controls, and explored its link to mortality. ⸻ ✅ Key…

DREAMM-7 Phase 3 Trial: BVd vs DVd in Relapsed/Refractory Multiple Myeloma 📌 Objective: Compare belantamab mafodotin + bortezomib + dexamethasone (BVd) vs daratumumab + bortezomib + dexamethasone (DVd) in RRMM patients after ≥1 prior line. 👥 Population: 494 patients…

📌 Study Summary: Serial Serum Mesothelin as a Biomarker in Pleural Mesothelioma (PM) 🧪 Purpose: To evaluate whether serial serum mesothelin (SM) levels can reliably track disease status in pleural mesothelioma, potentially offering a convenient adjunct to CT scans. 🧬…

🧪 Study Summary: Divergent Lesion Behavior in aHCC Challenges Use of PFS as a Surrogate Endpoint 📌 Purpose: To investigate how individual liver lesions behave over time in patients with advanced hepatocellular carcinoma (aHCC) receiving systemic therapy, and assess…

🧬 Real-World Patterns of gBRCA Testing & PARPi Use in HER2– Metastatic Breast Cancer (mBC) 📌 Purpose: To evaluate real-world trends in germline BRCA (gBRCA) testing and PARP inhibitor (PARPi) use in HER2-negative mBC from 2014–2022. 👥 Cohort: •15,006 HER2– mBC patients (US…

🧬 Phase I Trial: Cisplatin + Berzosertib + Veliparib for DDR Disruption 📌 Objective: To potentiate cisplatin’s effect by inducing a BRCA-null–like DNA damage response (DDR) phenotype using berzosertib (ATR inhibitor) and veliparib (PARP inhibitor). 👥 Design & Regimen:…

🤖 AI-Powered Prediction of Neoadjuvant Therapy Response in Breast Cancer 📊 Study Summary: Researchers developed an AI-driven Integrated Predictive Model (IPM) combining clinical, histopathological, and immune data to predict response to neoadjuvant therapy (NAT) in breast…

🧪 MATTERHORN Trial (NEJM July 2025): Perioperative Durvalumab + FLOT in Gastric & GEJ Cancer 📊 Design: Phase 3, randomized, double-blind trial (n=948) comparing durvalumab + FLOT vs placebo + FLOT in resectable stage II–IVA gastric/GEJ adenocarcinoma. ✅ Primary Endpoint:…

🔍 Conflicts of Interest in Oncology Trials: A 15-Year Review (JCO, 2010–2025) 📊 Study Objective: To assess the prevalence and trends of conflicts of interest (COIs) in oncology clinical trials published in Journal of Clinical Oncology over 15 years, using GPT-4o for automated…